Bastide Le Confort Médical (BLC) Q1 2026 TU earnings summary

Executive summary

• Achieved organic revenue growth of 8.3% in Q1 2025-2026, reaching €126.3 million, despite a 5% price cut in the sleep apnea segment effective April 1, 2025.

• Home healthcare services, representing 61.3% of revenue, grew organically by 10.7%.

• Homecare business posted 4.7% organic growth, with strong performance in healthcare institutions.

Financial highlights

• Q1 2025-2026 revenue: €126.3 million, up 8.0% as reported and 8.3% organically year-over-year.

• Homecare revenue: €49.0 million, up 4.7%; healthcare institutions revenue: €22.0 million, up 8.5%.

• Stores/online revenue: €27.0 million, up 1.7%.

• Respiratory business revenue: €41.5 million, up 11.7% organically; Nutrition-Perfusion-Diabetes-Stomatherapy: €35.8 million, up 9.5%.

Outlook and guidance

• Targeting annual revenue of at least €510 million for 2025-2026, with a stable margin around 9.0%.

• Guidance incorporates the full-year impact of a 5% price cut in sleep apnea (April 2025) and a further 4% reduction in April 2026.

• Confident in maintaining profitable growth and further debt reduction due to market growth, restructuring, and cost control.